Intralesional Tetracycline Injection in the Treatment of Chalazia (TET)
The investigators propose a study to investigate the role of tetracycline injection into chalazia versus observation alone. The investigators hypothesize tetracycline injection will result in a significant decrease in lesion size when compared to observation alone.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Intralesional Tetracycline Injection in the Treatment of Chalazia|
- Lesion size [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]The size of the lesion will be measured as well as photographed. Photographs will be reviewed by a masked chalazion photograph reviewer.
|Study Start Date:||March 2014|
|Estimated Study Completion Date:||March 2015|
|Estimated Primary Completion Date:||March 2015 (Final data collection date for primary outcome measure)|
No Intervention: Observation
30 patients will be randomized to observation alone. These patients will return 4 weeks (+/- 2 weeks) after their initial visit for lesion measurement and photographs.
30 patients will be randomized to treatment with an intralesional injection of 0.05 mL of 2% tetracycline solution. These subjects will return 4 weeks (+/- 2 weeks) after treatment for lesion measurement and photographs.
Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01763437
|Contact: Julian D Perry, M.D.||216 444 email@example.com|
|United States, Ohio|
|Cleveland Clinic Cole Eye Institute||Not yet recruiting|
|Cleveland, Ohio, United States, 44145|
|Contact: Laura Holody firstname.lastname@example.org|
|Principal Investigator: Julian D Perry, M.D.|
|Sub-Investigator: Bryan R Costin, M.D.|
|Principal Investigator:||Julian D Perry, M.D.||Cleveland Clinic Cole Eye Institute|